Featured publications

  • Molecular characterization of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis

    Authors: Pinyol R, Torrecilla S, Wang H, Montironi C, Piqué-Gili M, Torres-Martin M, Wei-Qiang L, Willoughby CE, Ramadori P, Andreu-Oller C, Taik P, Lee YA, Moeini A, Peix J, Faure-Dupuy S, Riedl T, Schuehle S, Oliveira CP, Alves VA, Boffetta P, Lachenmayer A, Roessler S, Minguez B, Schirmacher P, Dufour JF, Thung SN, Reeves HL, Carrilho FJ, Chang C, Uzilov AV, Heikenwalder M, Sanyal A, Friedman SL, Sia D, Llovet JM .
    Reference: Journal Of Hepatology 2021.
  • NASH limits anti-tumour surveillance in immunotherapy-treated HCC

    Authors: Pfister, Dominik; Nunez, Nicolas Gonzalo; Pinyol, Roser; Govaere, Olivier; Pinter, Matthias; Szydlowska, Marta; Gupta, Revant; Qiu, Mengjie; Deczkowska, Aleksandra; Weiner, Assaf; Mueller, Florian; Sinha, Ankit; Friebel, Ekaterina; Engleitner, Thomas; Lenggenhager, Daniela; Moncsek, Anja; Heide, Danijela; Stirm, Kristin; Kosla, Jan; Kotsiliti, Eleni; Leone, Valentina; Dudek, Michael; Yousuf, Suhail; Inverso, Donato; Singh, Indrabahadur; Teijeiro, Ana; Castet, Florian; Montironi, Carla; Haber, Philipp K.; Tiniakos, Dina; Bedossa, Pierre; Cockell, Simon; Younes, Ramy; Vacca, Michele; Marra, Fabio; Schattenberg, Jorn M.; Allison, Michael; Bugianesi, Elisabetta; Ratziu, Vlad; Pressiani, Tiziana; D'Alessio, Antonio; Personeni, Nicola; Rimassa, Lorenza; Daly, Ann K.; Scheiner, Bernhard; Pomej, Katharina; Kirstein, Martha M.; Vogel, Arndt; Peck-Radosavljevic, Markus; Hucke, Florian; Finkelmeier, Fabian; Waidmann, Oliver; Trojan, Jorg; Schulze, Kornelius; Wege, Henning; Koch, Sandra; Weinmann, Arndt; Bueter, Marco; Rossler, Fabian; Siebenhuner, Alexander; De Dosso, Sara; Mallm, Jan-Philipp; Umansky, Viktor; Jugold, Manfred; Luedde, Tom; Schietinger, Andrea; Schirmacher, Peter; Emu, Brinda; Augustin, Hellmut G.; Billeter, Adrian; Mueller-Stich, Beat; Kikuchi, Hiroto; Duda, Dan G.; Kutting, Fabian; Waldschmidt, Dirk-Thomas; Ebert, Matthias Philip; Rahbari, Nuh; Mei, Henrik E.; Schulz, Axel Ronald; Ringelhan, Marc; Malek, Nisar; Spahn, Stephan; Bitzer, Michael; Ruiz de Galarreta, Marina; Lujambio, Amaia; Dufour, Jean-Francois; Marron, Thomas U.; Kaseb, Ahmed; Kudo, Masatoshi; Huang, Yi-Hsiang; Djouder, Nabil; Wolter, Katharina; Zender, Lars; Marche, Parice N.; Decaens, Thomas; Pinato, David J.; Rad, Roland; Mertens, Joachim C.; Weber, Achim; Unger, Kristian; Meissner, Felix; Roth, Susanne; Jilkova, Zuzana Macek; Claassen, Manfred; Anstee, Quentin M.; Amit, Ido; Knolle, Percy; Becher, Burkhard; Llovet, Josep M.; Heikenwalder, Mathias;.
    Reference: Nature 2021.
  • Hepatocellular carcinoma

    Authors: Llovet JM; Kelley RK; Villanueva A; Singal AG; Pikarsky E; Roayaie S; Lencioni R; Koike K; Zucman-Rossi J; Finn RS.
    Reference: Nature Reviews Disease Primers 2021.
  • Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial

    Authors: Zhu, Andrew X.; Kang, Yoon-Koo; Yen, Chia-Jui; Finn, Richard S.; Galle, Peter R.; Llovet, Josep M.; Assenat, Eric; Brandi, Giovanni; Pracht, Marc; Lim, Ho Yeong; Rau, Kun-Ming; Motomura, Kenta; Ohno, Izumi; Merle, Philippe; Daniele, Bruno; Shin, Dong Bok; Gerken, Guido; Borg, Christophe; Hiriart, Jean-Baptiste; Okusaka, Takuji; Morimoto, Manabu; Hsu, Yanzhi; Abada, Paolo B.; Kudo, Masatoshi;REACH-2 Study Investigators.
    Reference: Lancet Oncology 2019.
  • Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features.

    Authors: Sia D, Jiao Y, Martinez-Quetglas I, Kuchuk O, Villacorta-Martin C, Castro de Moura M, Putra J, Camprecios G, Bassaganyas L, Akers N, Losic B, Waxman S, Thung SN, Mazzaferro V, Esteller M, Friedman SL, Schwartz M, Villanueva A, Llovet JM .
    Reference: Gastroenterology 2017.
  • Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets

    Authors: Schulze K., Imbeaud S., Letouzé E., Alexandrov L.B., Calderaro J., Rebouissou S., Couchy G., Meiller C., Shinde J., Soysouvanh F., Calatayud A.L., Pinyol R., Pelletier L., Balabaud C., Laurent A., Blanc J.F., Mazzaferro V., Calvo F., Villanueva A., Nault J.C., Bioulac-Sage P., Stratton M.R., Llovet J.M., Zucman-Rossi J..
    Reference: Nature Genetics 2015.
  • Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma

    Authors: Sia, Daniela; Losic, Bojan; Moeini, Agrin; Cabellos, Laia; Hao, Ke; Revill, Kate; Bonal, Dennis; Miltiadous, Oriana; Zhang, Zhongyang; Hoshida, Yujin; Cornella, Helena; Castillo-Martin, Mireia; Pinyol, Roser; Kasai, Yumi; Roayaie, Sasan; Thung, Swan N; Fuster, Josep; Schwartz, Myron E; Waxman, Samuel; Cordon-Cardo, Carlos; Schadt, Eric; Mazzaferro, Vincenzo; Llovet, Josep M.
    Reference: Nature Communications 2015.
  • Gene Expression in Fixed Tissues and Outcome in Hepatocellular Carcinoma

    Authors: Hoshida, Yujin; Villanueva, Augusto; Kobayashi, Masahiro; Peix, Judit; Chiang, Derek Y; Camargo, Amy; Gupta, Supriya; Moore, Jamie; Wrobel, Matthew J; Lerner, Jim; Reich, Michael; Chan, Jennifer A; Glickman, Jonathan N; Ikeda, Kenji; Hashimoto, Masaji; Watanabe, Goro; Daidone, Maria G; Roayaie, Sasan; Schwartz, Myron; Thung, Swan; Salvesen, Helga B; Gabriel, Stacey; Mazzaferro, Vincenzo; Bruix, Jordi; Friedman, Scott L; Kumada, Hiromitsu; Llovet, Josep M; Golub, Todd R.
    Reference: New England Journal Of Medicine 2008.
  • Sorafenib in advanced hepatocellular carcinoma.

    Authors: Llovet Bayer, Josep M..
    Reference: The New England Journal Of Medicine 2008.

Featured Projects

  • HUNTER-Hepatocellular Carcinoma Expediter Network CRUK, AEDD, AIRC Accelerator Award.

    Principal investigator: Josep M. Llovet Bayer
    Funder: Asociación Española Contra el Cáncer (AECC) ; CRUK, AECC, AIRC Accelerator Award
    Code: AECC-Accelerator Award 2017
    Duration: 01/01/2019 - 31/12/2023
  • Mechanisms underlying hepatocellular carcinoma pathogenesis and impact of co-morbidities (HEP-CAR)

    Principal investigator: Josep M. Llovet Bayer
    Funder: HORIZON 2020. Call H2020-PHC-2015 ; IDIBAPS-Hospital Clínic (Sede); Institut d'Investigacions Biomèdiques August Pi i Sunyer (Entidad de origen)
    Code: 667273
    Duration: 01/01/2016 - 31/12/2019
  • Integrative genomic analysis of intrahepatic cholangiocarcinoma (AECC_Grupo Estable 11)

    Principal investigator: Josep Maria Llovet Bayer
    Funder: Institut d`Investigacions Biomèdiques August Pi i Sunyer (Sede); Fundacion Cientifica Asociacion Espanola Contra el Cancer (AECC)
    Code: GCA110347LLOV
    Duration: 01/09/2011 - 31/08/2018
  • Genomic predictors and oncogenic drivers in hepatocellular carcinoma (HEPTROMIC)

    Principal investigator: Josep M. Llovet Bayer
    Funder: European Comission (EC)
    Code: FP7-Health-2ST-10 (259744)
    Duration: 01/11/2010 - 26/11/2014
  • Integrative genomic analysis in hepatocellular carcinoma

    Principal investigator: Josep M Llovet Bayer
    Code: 5R01DK076986-05
    Duration: 10/08/2007 - 31/07/2012